Methods, Interpretation and Applications of HIV-1 Viral Load Measurements

Clinical Microbiology Newsletter

Volumn 19, Issue 1, 1997, Pages 1-5

  Caliendo, Angela M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002752241     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0196-4399(97)89844-3     Document Type: Article

References (22)

1. Mellors, J.W., et al. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573-579.
2. O'Brien, T.R., et al. 1996. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 276:105-110.
3. Mellors, J.W., et al. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
4. O'Brien, W.A., et al. 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334:426-431.
5. Katzenstein, D.A., et al. 1996. Virologic and immunologic markers and clinical outcomes after nucleoside therapy in adults with 200 to 500 cells per cubic millimeter. N. Engl. J. Med. 335:1091-1098.
6. Heath-Chiozzi, M., et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency, abstract LB6b.. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC: 1996:
7. Coombs, R.W., et al. 1996. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. 174:704-712.
8. Welles, S.L., et al. 1996. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J. Infect. Dis. 174:696-703.
9. Eron, J.J., et al. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
10. Ho, D.D., et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
11. Wei, X., et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
12. Saag, M.S., et al. 1996. HIV viral load markers in clinical practice. Nature Med. 2:625-629.
13. Mulder, J. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
14. Pachl, C., et al. 1995. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. AIDS 8:446-454.
15. Van Gemen, B., et al. 1993. Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 7 (suppl 2):S107-S110.
16. Dickover, R., et al. 1996. Stability of HIV-1 RNA in whole blood stored at room temperature and effect of anticoagulant, abstract I23. 36th ICCAC. New Orleans, LA.
17. Boom, R., et al. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
18. Donovan, R.M., et al. 1996. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J. Infect. Dis. 174:410-413.
19. O'Brien, W.A., et al. 1995. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:1082-1089.
20. Staprans, S.I., et al. 1995. Activation of virus replication after vaccination of HIV-1 infected individuals. J. Exp. Med. 182:1727-1737.
21. Irwin, K., et al. 1996. Unusual HIV serotype in a Bronx community with high prevalence, abstract WE.C 345. XI International Conference on AIDS. Vancouver, Canada.
22. Todd, J., et al. 1994. Quantitation of human immunodeficiency virus plasma RNA bt branched DNA and reverse transcription coupled polymerase chain reaction assay methods: A critical evaluation of accuracy and reproducibility. Immunother. Infect. Dis. 6:233-239.